Skip to main content

Advertisement

Table 2 Demographics and cerebrospinal fluid biomarker levels of control group and cerebrospinal fluid Alzheimer’s disease biomarker-defined subgroups with dementia

From: Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup

  Control AD biomarker-negative dementia (CSF T-tau/Aβ42 < 1.0) AD biomarker-positive dementia (CSF T-tau/Aβ42 > 1.0)
No. of subjects 17 49 15
Male sex, n (% group) 6 (54.5) 36 (73.4) 9 (60.0)
Age at CSF, years, mean (SD) 63.7 (6.4) 64.1 (6.7) 65.9 (6.0)
Age at onset, years, mean (SD) n/a 58.6 (6.8) 62.4 (6.7)
Disease duration at CSF collection, years, mean (SD); median (IQR) n/a 5.6 (4.1); 4.6 (3.1–6.6) 3.5 (2.1); 2.9 (1.7–5.1)
CSF sTREM2, ng/ml, mean (SD) 6.8 (1.6) 6.9 (3.0) 9.0 (3.6)
CSF Aβ42, pg/ml, mean (SD) 1032.2 (214.3) 833.9 (265.4) 510.5 (165.7)
CSF T-tau, pg/ml, mean (SD) 332.6 (82.4) 373.5 (173.0) 1047.2 (511.3)
CSF P-tau, pg/ml, mean (SD) 52.7 (10.6) 44.8 (15.3) 97.0 (34.3)
CSF T-tau/Aβ42 ratio, median (IQR) 0.3 (0.2–0.5) 0.4 (0.3–0.7) 1.6 (1.2–3.2)
  1. AD Alzheimer’s disease, n/a Not applicable; for others, see list of abbreviations
  2. The dementia subgroups include individuals with FTD (bvFTD and PPA) defined by their CSF biomarker profile as stated